Sucampo Pharmaceuticals — Investor Presentation (February 2015)
20 slides from Sucampo Pharmaceuticals's investor presentation, Feb 23, 2015
Slide 1: Sucampo Pharmaceuticals, Inc. - Peter Greenleaf, CEO
sharmaceuticals, Inc. Peter Greenleaf Chief Executive Officer ¢ @ SUCAMPO The Science of Innovation
Slide 2: Forward-Looking Statements
Forward-Looking Statements: product potential, future others, and/or regulatory actions. new information, ¢ ? SUCAMPO 2 The Science of Innovation
Slide 3: Investment Highlights
Investment Highlights al ith diff p a large unmet need Li 2 hi t PP revenue growth . , lable to d tainable long term growth 7 t Il build g foundation = Well = Strong fi i i heet and n position = Deep ith p peri i product development ¢ ? SUCAMPO 3 The Science of Innovation
Slide 4: Revenue & Market Value
Revenue & Market Value lear Strategy to Metho ali a TS = Focus efforts and pt te overall abilities : = capability = Secure and grow AMITIZA revenues (Zia to ensure coisa sustain: ani growt! : eae partne i ing eatin of patent investment (ongoing) + Diversify investor base = Continue tearatient capabi
Slide 5: Management team
Peter Greenleaf @riistogenics [hg] Setmonafefinen Chief Executive Officer tea en © centocor Peter Kiener, D.Phil 4 : v —Ambrx Chief Scientific Officer ee yes Sib a I Zyngenia Peter Lichtlen, M.D., Ph.D. Matthias Al db Novartis Guia Miesierccte CYTOS micr@met Business Development & Licensing ae Max D
Slide 6: AMITIZA (lubiprostone)
See== jl amitiza lubiprostone e 9 SUCAMPO 6 The Science of Innovation
Slide 7: Unique and Highly-Differentiated Product
que and Highly-Differentiatéd Product bel i tipation market: 3 indications, 3 patient types I * CIC: Chronic Idiopathic Constipation + IBS: ip + OIC: Op Adut a F product: over 9M p ipti: 20 = Only f acti 4s 2. function = Key product characteristics . ee ing = Well-tolerated product with established
Slide 8: Constipation market TRx by category
at MATTY TRx by Cat 201 ; ATTY TRx thn 48.2 M TRX Sorbitol, Bulk Fiber (Citrucel, Genetic mineral oi lass Linaclotide Fleet Enemas (1%) ANITIZA. \, 3% 2% Stool softeners 3% wat stim ax (Senna 8) 4% Other Branded Generic Qsmi Prep, PEG preps 0% Sorbitol, minora oil Presray Bvacuanis 1% ] 0% 58520 tar
Slide 9: TRx Scripts
TRx Scripts 1,360,000 4,300,000 41,250,000 4,200,000 4,180,000 41,100,000 1,050,000 2010 2011 Units 2012 2013 2014 Estimate 1,400,000 > 1,200,000 + 1,000,000 + 800,000 - TRx Seripts* 600,000 + 400,000 + 200,000 + 4,241,304 489,543 7,652 2012 2013 2014 ¢€ ? SUCAMPO The Science of Innovation
Slide 10: Yearly Increases
¥ Yearly Increases v poresment ¥ Gross-to-net cap + 50160 gross fon Sueemee Underpenetrated profit split on markets with generic unsatisfied poets easy Gen ‘akeda + 50/50 gross agr emer ‘ profit split on v ys Targeting brand incl. LCM Yo Y ac dnt 20% of brand sales
Slide 11: Global regulatory status and Takeda partnership
Canada CIC and OIC. (filed 10/30/14) Switzerland us. CIC and O1C CIC, IBS-C and olc Latin America ROW Territories TBD TBD is #1 GI company we Takeda has ae a all markets except se racer and China * MRP filed in Austria, Belgium, Germany, Italy, Ireland, Luxembourg, Netherlands, and Spain; @ SUCAMPO
Slide 12: AMITIZA Life Cycle Management
AMITIZA Life Cycle Management Exynand ANMITIZA f I th igh new and new indication 1. New Formulation capsules, or naso-gastric tube fed patients . i 409 difficult swallowing pills * Next step: Phase 3 commence 2H 2015 2 . New Pediatric F » US Prevalence: 18% iatri i + Unmet need: No FD, box warning f
Slide 13: $
$ SUCAMPO The Science of Innovation
Slide 14: Clinical Focus
CLINICAL FOCUS. (AGE OF CLINICAL DEVELOPMENT TIMELINE TARGETS [eso coneanos [maser | PHASE 3 ROVAL LLubiprostone — Pediatric Functional Constipation (6 years-17 years) | Lubiprostone — Alternate Formulation (Adults) Lifecycle Management biprostone — Alternate Formulation = redatie 2 Functional Const
Slide 15: Sucampo
oO oO oO oO $ sucampo 15 The Science of Innovation
Slide 16: $
$ SUCAMPO The Science of Innovation
Slide 17: Cash & Equivalents and guidance
Cash & Equivalents: Net Income, excluding special items EPS, excluding special iter AMITIZA US. Net Sal Net income, excluding special items Sales (as reported by Takeda for royalty calculation purposes): Raised full year 2014 guidance", excluding special items *$14M Upfront Payment from Takeda recei
Slide 18: Upcoming Milestones
Upcoming Milestones ev Global partnership agreement for AMITIZA jpdated on AMITIZA alternate formulation and PFC development Filed AMITIZA (CIC and OIC) for approval in Canada Initiated MRP to secure approval for AMITIZA (CIC) in ac n ion channel activator program for LSS 2FPI 4H 2015 2H 2015 years)
Slide 19: Investment Highlights
Investment Highlights = Lead product with differentiated profile in an attractive market with a large unmet need aBI h yt revenue growth hips provide global reach and drive outsized = Multiple levers available to drive sustainable long term growth = Robust product pipeline that will build on a stron
Slide 20: $
$ SUCAMPO The Science of Innovation
Sucampo Pharmaceuticals — Investor Presentation (February 2015) on 6ix